EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 164 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,882 | +1943.4% | 15,465 | +2418.7% | 0.00% | – |
| Q2 2023 | $11,935 | -88.0% | 614 | -82.4% | 0.00% | – |
| Q1 2023 | $99,096 | -67.1% | 3,493 | -66.1% | 0.00% | -100.0% |
| Q4 2022 | $300,864 | +227.0% | 10,293 | +194.7% | 0.00% | – |
| Q3 2022 | $92,000 | -67.5% | 3,493 | -45.6% | 0.00% | -100.0% |
| Q2 2022 | $283,000 | -47.9% | 6,426 | -41.7% | 0.00% | 0.0% |
| Q1 2022 | $543,000 | -18.2% | 11,013 | -15.9% | 0.00% | 0.0% |
| Q4 2021 | $664,000 | -37.5% | 13,096 | -31.3% | 0.00% | -50.0% |
| Q3 2021 | $1,062,000 | -41.8% | 19,068 | -55.6% | 0.00% | -33.3% |
| Q2 2021 | $1,824,000 | -55.0% | 42,913 | -56.0% | 0.00% | -57.1% |
| Q1 2021 | $4,057,000 | +2.3% | 97,533 | +14.5% | 0.01% | -12.5% |
| Q4 2020 | $3,964,000 | +1.8% | 85,212 | -7.3% | 0.01% | 0.0% |
| Q3 2020 | $3,892,000 | -9.3% | 91,888 | +2.6% | 0.01% | -20.0% |
| Q2 2020 | $4,293,000 | +42.6% | 89,535 | +36.7% | 0.01% | +25.0% |
| Q1 2020 | $3,010,000 | -11.6% | 65,495 | +15.5% | 0.01% | +33.3% |
| Q4 2019 | $3,405,000 | -14.8% | 56,692 | -19.8% | 0.01% | -25.0% |
| Q3 2019 | $3,997,000 | +80.2% | 70,664 | +77.3% | 0.01% | +100.0% |
| Q2 2019 | $2,218,000 | +93.9% | 39,845 | +75.9% | 0.00% | +100.0% |
| Q1 2019 | $1,144,000 | +98.6% | 22,655 | +58.3% | 0.00% | +100.0% |
| Q4 2018 | $576,000 | +357.1% | 14,307 | +684.4% | 0.00% | – |
| Q3 2018 | $126,000 | -71.4% | 1,824 | -68.7% | 0.00% | -100.0% |
| Q2 2018 | $441,000 | +45.1% | 5,832 | +0.9% | 0.00% | 0.0% |
| Q1 2018 | $304,000 | +533.3% | 5,779 | +563.5% | 0.00% | – |
| Q4 2017 | $48,000 | -11.1% | 871 | -4.5% | 0.00% | – |
| Q3 2017 | $54,000 | -98.5% | 912 | -98.0% | 0.00% | -100.0% |
| Q2 2017 | $3,634,000 | +7025.5% | 46,084 | +7357.0% | 0.01% | – |
| Q1 2017 | $51,000 | -97.4% | 618 | -97.5% | 0.00% | -100.0% |
| Q4 2016 | $1,935,000 | – | 24,553 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |